View profile

FarmaKology Newsletter - Issue #55

Revue
 
Would you like to submit an article, some interesting news, or get your startup featured? Send whatev
 

FarmaKology

August 19 · Issue #55 · View online
FarmaKology is a newsletter that brings you the latest news, research, job opportunities in the Pharma world, and much more! If you would like to be featured in the newsletter, sponsor an issue, or need anything, please feel free to get in touch with me at "abdul@farmakology.com".

Would you like to submit an article, some interesting news, or get your startup featured? Send whatever you have to abdul@farmakology.com, and happy to have you featured on our newsletter (+7477 Subscribers ) !

Today's Startup
AI Therapeutics
AI Therapeutics
AI Therapeutics
AI Therapeutics was founded in 2013 as LAM Therapeutics with a mission to advance the clinical development of new therapies to treat Lymphangioleiomyomatosis (LAM) and other diseases. In 2018 we changed our name to AI Therapeutics. Working with a dedicated team of scientific, clinical, and drug development experts, AI Therapeutics is pioneering deep learning-based AI to outsmart cancer and rare diseases.
News
Oil-Dri Corporation of America , a leading manufacturer of sorbent minerals, parent company to Amlan International, announces that the European Patent Office has issued Patent EP 2906238. The patent covers the unique formulation of two existing mineral-based natural feed additives, Varium® for poultry and NeoPrime® for swine, that are helping global animal protein producers thrive in an era of antibiotic-free production.
NVX-CoV2373 is produced by the biotech company, Novavax . Novavax is a late-stage biotechnology company that develops next-generation vaccines for serious infectious diseases.Wits Professor of Vaccinology Shabir Madhi will lead the Novavax clinical trial in South Africa after having engaged personally with Novavax to motivate for clinical development of the vaccine to be undertaken in this country.
The FDA has accepted a Biologics License Application for a new 4-week fixed-dose regimen containing durvalumab (Imfinzi) and granted it Priority Review for the approved indications of non–small cell lung cancer (NSCLC), as well as bladder cancer. Durvalumab’s developer, AstraZeneca, announced this regulatory action in a press release, noting that the new dosing schedule could reduce medical visits by half.
MaxCyte, Inc., a global cell-based therapies and life sciences company, today announces the expansion of subsidiary CARMA Cell Therapies’ ongoing Phase I intraperitoneal delivery and dose-escalation trial of MCY-M11, its lead anti-mesothelin CAR-PBMC cell therapy candidate. The expansion will involve a new parallel cohort of patients and the initiation of two additional clinical sites.
Research & Study
Podcast
Episode 143 - Should Your Kids Go Back To School? Pharmaceutical Companies Are Cooperating! Vaccine Updates Too Wild Health podcast
Job Opportunities
Upcoming Webinar
Video
The Pharmaceutical Industry
FarmaKology
FarmaKology
Did you enjoy this issue?
If you don't want these updates anymore, please unsubscribe here.
If you were forwarded this newsletter and you like it, you can subscribe here.
Powered by Revue